259809-74-0

Basic information

• Product Name: 5-tert-butyl 2-methyl 6,7-dihydrooxazolo[5,4-c]pyridine-2,5(4H)-dicarboxylate
• Synonyms: 5-tert-butyl 2-methyl 6,7-dihydrooxazolo[5,4-c]pyridine-2,5(4H)-dicarboxylate;5-tert-butyl 2-Methyl 4H,5H,6H,7H-[1,3]oxazolo[5,4-c]pyridine-2,5-dicarboxylate;5-tert-butyl 2-ethyl 6,7-dihydrooxazolo[5,4-c]pyridine-2,5(4H)-dicarboxylate
• CAS NO: 259809-74-0
• Molecular Formula: C13H18N2O5
• Molecular Weight: 282.29
• Product Categories: CHIRAL CHEMICALS
• Mol File: 259809-74-0.mol

Chemical Properties

• Boiling Point: 395.6 °C at 760 mmHg
• Flash Point: 193.1 °C
• Appearance: /
• Density: 1.235
• Vapor Pressure: 1.81E-06mmHg at 25°C
• Refractive Index: 1.515
• PKA: -1.61±0.20(Predicted)
• CAS DataBase Reference: 5-tert-butyl 2-methyl 6,7-dihydrooxazolo[5,4-c]pyridine-2,5(4H)-dicarboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: 5-tert-butyl 2-methyl 6,7-dihydrooxazolo[5,4-c]pyridine-2,5(4H)-dicarboxylate(259809-74-0)
• EPA Substance Registry System: 5-tert-butyl 2-methyl 6,7-dihydrooxazolo[5,4-c]pyridine-2,5(4H)-dicarboxylate(259809-74-0)

Safety Data

• Hazardous Substances Data: 259809-74-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research and Development:
5-tert-butyl 2-methyl 6,7-dihydrooxazolo[5,4-c]pyridine-2,5(4H)-dicarboxylate is used as a research compound for its potential therapeutic applications. Its ability to interact with biological systems makes it a promising candidate for the development of new drugs and therapies.
Used in Neurological Disorders Treatment:
In the medical field, 5-tert-butyl 2-methyl 6,7-dihydrooxazolo[5,4-c]pyridine-2,5(4H)-dicarboxylate is being studied for its potential use in the treatment of neurological disorders. Its interaction with biological systems may offer new avenues for managing and treating these conditions.
Used as a Potential Analgesic:
5-tert-butyl 2-methyl 6,7-dihydrooxazolo[5,4-c]pyridine-2,5(4H)-dicarboxylate is also being investigated for its potential as an analgesic. Its ability to interact with biological systems could provide relief from pain and discomfort, offering a new option for pain management.
Used in Antiviral and Antibacterial Applications:
In the field of infectious diseases, 5-tert-butyl 2-methyl 6,7-dihydrooxazolo[5,4-c]pyridine-2,5(4H)-dicarboxylate has been studied for its potential antiviral and antibacterial properties. Its interaction with biological systems may contribute to the development of new treatments for viral and bacterial infections.
Used in Chemical Synthesis:
5-tert-butyl 2-methyl 6,7-dihydrooxazolo[5,4-c]pyridine-2,5(4H)-dicarboxylate is also used in chemical synthesis, where its unique structure and properties can be utilized to create new compounds with various applications in different industries.

InChI:InChI=1/C13H18N2O5/c1-13(2,3)20-12(17)15-6-5-8-9(7-15)19-10(14-8)11(16)18-4/h5-7H2,1-4H3

Upstream product

• 259809-73-9 5-(tert-Butoxycarbonyl)-2-formyl-4,5,6,7-tetrahydro-oxazolo[5,4-c]pyridine 
• 259809-67-1 2-[(E)-2-phenylethenyl]oxazole-4-carbaldehyde 
• 259809-72-8 5-(tert-butoxycarbonyl)-2-(trans-β-styryl)-4,5,6,7-tetrahydrooxazolo[5,4-c]pyridine 
• 259809-71-7 4-[2-(tert-butoxycarbonylamino)ethyl]-2-(trans-β-styryl)oxazole 
• 259809-69-3 2-{2-[(E)-2-Phenylethenyl]oxazol-4-yl}-1-ethanol 
• 259809-68-2 2-[(E)-2-Phenylethenyl]-4-vinyloxazole 
• 67-56-1 methanol 
• 259809-70-6 2-(2-{2-[(E)-2-Phenylethenyl]oxazol-4-yl}ethyl)-1H-isoindol-1,3(2H)-dione 

Relevant articles and documents

Design, synthesis, and biological activity of novel factor Xa inhibitors: Improving metabolic stability by S1 and S4 ligand modification

Serine protease factor xa (fXa) inhibitor 1 showed good ex vivo anti-fXa activity upon oral administration in rats. However, it has been revealed that 1 had low metabolic stability against human liver microsomes. To improve the metabolic stability, we att

Diamine derivatives

A compound represented by the general formula (1): Q1-Q2-T0-N(R1)-Q3-N(R2)-T1-Q4??(1) wherein R1 and R2 are hydrogen atoms or the like; Q1 is a saturated or unsaturated, 5- or 6-membered cyclic hydrocarbon group which may be substituted, or the like; Q2 is a single bond or the like; Q3 is a group in which Q5 is an alkylene group having 1 to 8 carbon atoms, or the like; and T0 and T1 are carbonyl groups or the like; a salt thereof, a solvate thereof, or an N-oxide thereof. The compound is useful as an agent for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.

DIAMINE DERIVATIVES

A compound represented by formula (1):Q1-Q2-To-N(R1) -Q3-N(R2)-T1-Q4 [wherein R1 and R2 are hydrogen atoms or the like; Q1 is a saturated or unsaturated, 5- or 6- membered cyclic hydrocarbon group which may be substituted, or the like; Q2 is a single bond or the like; Q3 represents the following group: (wherein Q5 is an alkylene group having 1 to 8 carbon atoms, or the like); and T0 and T1 are carbonyl groups or the like], a salt thereof, a solvate thereof, or an N-oxide thereof. The compound is useful as an agent for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after artificial valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.

DIAMINE DERIVATIVES

A compound represented by the general formula (1):Q1-Q2-T0-N(R1)-Q3-N(R2)-T1-Q4 wherein R1 and R2 are hydrogen atoms or the like; Q1 is a saturated or unsaturated, 5- or 6- membered cyclic hydrocarbon group which may be substituted, or the like; Q2 is a single bond or the like; Q3 is a group in which Q5 is an alkylene group having 1 to 8 carbon atoms, or the like; and T0 and T1 are carbonyl groups or the like; a salt thereof, a solvate thereof, or an N-oxide thereof. The compound is useful as an agent for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.

ETHYLENEDIAMINE DERIVATIVES

The invention relates a compound represented by the formula (1):Q1-Q2-C(=O)-N(R1)-Q3-N(R2)-T1-Q4 wherein R1 and R2 represent H or the like; Q1 represents an aromatic ring, heterocyclic ring or the like; Q2 represents a single bond, aromatic ring, heterocyclic ring or the like; Q3 represents a group or the like, Q4 represents an aromatic ring, heterocyclic ring or the like; and T1 represents -CO- or -SO2-, and a medicine which comprises the compound and is useful for thrombosis and embolism.